Correction to today's FierceBiotech

FierceBiotech's subject line in today's e-mail for the report incorrectly identified Innate's partner in a new deal. The pact was inked with Bristol-Myers Squibb, as we report in the story, not Sanofi. We regret the error. Read the story

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.